Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.
Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain. Multicenter, Randomized, Controlled Study
University Hospital, Rouen
200 participants
Jan 18, 2024
INTERVENTIONAL
Conditions
Summary
The aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (PPP) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.
Eligibility
Inclusion Criteria3
- Patient hospitalized in the rheumatology department
- Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology
- Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion
Exclusion Criteria5
- Patient with cancer or fibromyalgia already diagnosed at inclusion
- Patient with poor French language skills
- Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion
- Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment
- Patient already included in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05905146